[1] Thulin Å, Christersson C, Alfredsson J, et al. Circulating cell-derived microparticles as biomarkers in cardiovascular disease[J]. Biomark Med, 2016, 10(9):1009-1022. [2] Jia L, Fan J, Cui W, et al. Endothelial cell-derived microparticles from patients with obstructive sleep apnea hypoxia syndrome and coronary artery disease increase aortic endothelial cell dysfunction[J]. Cell Physiol Biochem, 2017, 43(6):2562-2570. [3] Wang Y, Zhang L, Li Y, et al. Exosomes/microvesicles fro m induced pluripotent stem cells deliver cardioprotective miRNAs and prevent cardiomyocyte apoptosis in the ischemic myocardium[J]. Int J Cardiol, 2015, 192:61-69. [4] Zhang Q, Shang M, Zhang MX, et al. Microvesicles derived fro m hypoxia/reoxygenation-treated human umbilical vein endothelial cells promote apoptosis and oxidative stress in H9c2 cardiomyocytes[J]. BMC Cell Biol, 2016, 17(1):25-34. [5] Zhang KW, Wang SX, Li YY, et al. Iptakalim ameliorates relaxation of rat thoracic aortic rings impaired by microvesicles derived from hypoxia/reoxygenation-treated HUVECs[J]. Chin J Appl Physiol, 2016, 32(6):481-486. [6] Ren S, Zhang H, Mu Y, et al. Pharmacological effects of Astragaloside IV:a literature review[J]. J Tradit Chin Med, 2013, 33(3):413-416. [7] 王媛媛, 彭洋, 张琦, 等. ERK1/2信号通路对黄芪苷Ⅳ抗H2O2诱导H9c2细胞氧化损伤的作用[J]. 中国应用生理学杂志, 2011, 27(3):363-367. [8] Hu G, Li X, Zhang S, et al. Association of rat thoracic aorta dilatation by astragaloside IV with the generation of endothelium-derived hyperpolarizing factors and nitric oxide, and the blockade of Ca2+ channels[J]. Biomed Rep, 2016, 5(1):27-34. [9] Jia LX, Zhang WM, Li TT, et al. ER stress dependent microparticles derived from smooth muscle cells promote endothelial dysfunction during thoracic aortic aneurysm and dissection[J]. Clin Sci, 2017, 131(12):1287-1299. [10] Bei Y, Das S, Rodosthenous RS, et al. Extracellular vesicles in cardiovascular theranostics[J]. Theranostics, 2017, 7(17):4168-4182. [11] Pan S, Yang X, Jia Y, et al. Microvesicle-shuttled miR130b reduces fat deposition in recipient primary cultured porcine adipocytes by inhibiting PPAR-gama expression[J]. J Cell Physiol, 2014, 229(5):631-639. [12] Liu H, Jing X, Dong A, et al. Overexpression of TIMP3 protects against cardiac ischemia/reperfusion injury by inhibiting myocardial apoptosis through ROS/Mapks pathway[J]. Cell Physiol Biochem, 2017, 44(3):1011-1023. [13] Song K, Wang Y, Sheng J, et al. Effects of dabigatran regulates no-reflow phenomenon in acute myocardial infarction mice through anti-inflammatory and anti-oxidative activities and connective tissue growth factor expression[J]. Mol Med Rep, 2018, 17(1):580-585. [14] Ebner A, Kuerbis N, Brandt A, et al. Endothelial nitric oxide synthase-induced hypertrophy and vascular dysfunction contribute to the left ventricular dysfunction in caveolin-1 mice[J]. Can J Cardiol, 2017, 33(12):1716-1724. [15] Chen YF, Gui DK, Chen JG, et al. Down-regulation of PERK-ATF4-CHOP pathway by Astragaloside IV is associated with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis in diabetic rats[J]. Cell Physiol Biochem, 2014, 33(6):1975-1987. [16] Sun Y, Jiang C, Jiang J, et al. Dexmedetomidine protects mice against myocardium ischaemic/reperfusion injury by activating an AMPK/PI3K/Akt/eNOS pathway[J]. Clin Exp Pharmacol Physiol, 2017, 44(9):946-953. [17] Yang K, Zhang H, Luo Y, et al. Gypenoside XVⅡ prevents atherosclerosis by attenuating endothelial apoptosis and oxidative stress:insight into the ERα-mediated PI3K/Akt pathway[J]. Int J Mol Sci, 2017, 18(2)pii:E77. [18] 张琦, 彭洋, 宋君秋, 等. 黄芪苷Ⅳ通过PI3K/Akt信号通路抗H2O2诱导的H9c2细胞氧化损伤[J]. 中草药, 2010, 41(6):955-959. [19] Jeong JJ, Ha YM, Jin YC, et al. Rutin from Lonicera japonica inhibits myocardial ischemia/reperfusion-induced apoptosis in vivo and protects H9c2 cells against hydrogen peroxide-mediated injury via ERK1/2 and PI3K/Akt signals in vitro[J]. Food Chem Toxicol, 2009, 47(7):1569-1576. [20] Jiang BE, Yang Y, Jin H, et al. Astragaloside IV attenuates lipolysis and improves insulin resistance induced by TNFαin 3T3-L1 adipocytes[J]. Phytother Res, 2008, 22(11):1434-1439. [21] Li L, Hou X, Xu R, et al. Research review on the pharmacological effects of astragaloside IV[J]. Fundam Clin Pharmacol, 2017, 31(1):17-36. |